HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS

Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of failing to disclose material information during the class period, which has led to a significant drop in share price following a partnership termination announcement by Novo Nordisk [3][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to file lead plaintiff applications in the securities class action lawsuits against Hims, specifically for those who purchased securities between April 29, 2025, and June 23, 2025 [1]. - The lawsuits are pending in the United States District Court for the Northern District of California, with the first case being Sookdeo v. Hims & Hers Health, Inc. and a subsequent case expanding the class period [5]. Group 2: Company Impact - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and concerns over patient safety due to potentially unsafe ingredients in products sold by Hims [4]. - Following this announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on unusually heavy trading volume [4].